fashion -WSS

fashion

author：comprehensive 2025-09-30 21:07:40 - browse：7963

Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Will the FTC rein in IQVIA's health data empire?

leisure time

knowledge

WSS

What it's like to live with paralysis for one psychologist

What it's like to live with paralysis for one psychologist

Commercial surrogacy can be ethical, despite pope’s claims

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Truvian presents data for its desktop blood

Commercial surrogacy can be ethical, despite pope’s claims

explore

fashion

focus

Wildfire smoke exposes gaps in outdoor worker protections

UHS says company favors patients whose insurance pays more

Walensky prepares to leave CDC — and Congress — behind

Democrats decry new health bill for going easy on private equity

Dobbs anniversary: the lost opportunity of abortion as health care

What it's like to live with paralysis for one psychologist

Duchenne breakthrough therapy leaves behind pioneering families

Senate panel puts off hardest PBM reforms for another day

At least 13 dead in Texas as scorching temps continue

SAMSHA loosens regulations on methadone treatment centers

entertainment

Search called off for baby washed away in Pennsylvania flash flood

Will the FTC rein in IQVIA's health data empire?

Congressmen charge Covid hearing ‘could have been an email’

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Vertigo drug brings hope for rare neuron disorder, Niemann

leisure time

knowledge

focus

explore